Document is current
Any future updates will be listed below
-
Authors
Feenstra, Lian
Zeper, Lara W.
van de Langenberg, Brenda
Kahlman, Eveline J. E. M.
de La Roij, Guido
Reijrink, Melanie
Bernay, Benoit
Chatre, Laurent
Kuipers, Jeroen
Giepmans, Ben N. G.
Mastik, Mirjam F.
Kooistra, Wierd
Lodewijk, Monique E.
Zuidscherwoude, Malou
Pol, Robert A.
,
Annema, Coby
Bakker, Stephan J. L.
Berger, Stefan P.
Blokzijl, Hans
Bodewes, Frank A. J. A.
de Boer, Marieke T.
Damman, Kevin
de Borst, Martin H.
Diepstra, Arjan
Dijkstra, Gerard
Douwes, Rianne M.
Doorenbos, Caecilia S. E.
Eisenga, Michele F.
Erasmus, Michiel E.
Gan, C. Tji
Gomes Neto, Antonio W.
Hak, Eelko
Hepkema, Bouke G.
van den Heuvel, Marius C.
Klont, Frank
Knobbe, Tim J.
Kremer, Daan
van Leer-Buter, Coretta
Leuvenink, Henri G. D.
van Londen, Marco
Lexmond, Willem S.
de Meijer, Vincent E.
Niesters, Hubert G. M.
Nieuwenhuis-Moeke, Gertrude J.
van Pelt, L. Joost
Porte, Robert J.
Ranchor, Adelita V.
Sanders, Jan Stephan F.
Siebelink, Marion J.
Slart, Riemer J. H. J. A.
Swarte, J. Cas
Touw, Daan J.
te Velde-Keyzer, Charlotte A.
Verschuuren, Erik A. M.
Vos, Michel J.
Weersma, Rinse K.
Smith, Edward. R.
Krenning, Guido
de Baaij, Jeroen H. F.
Hillebrands, Jan-Luuk https://orcid.org/0000-0003-3135-3274
Hoenderop, Joost G. J. https://orcid.org/0000-0002-1816-8544
-
Funding
Funding for this research was provided by:
Nierstichting (16TKI02, 21OK022)
Health~Holland (LSHM17034-SGF)
Universitair Medisch Centrum Groningen
ZonMw (91111.006)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (184.034.014)
- License Information
-
More Information
Article History
Received: 29 November 2024
Revised: 12 March 2025
Accepted: 7 April 2025
First Online: 26 April 2025
Declarations
:
: G. Krenning is Chief Scientific Officer of Sulfateq B.V. (Groningen, the Netherlands), a company that develops small molecule therapeutics. Sulfateq B.V. has no small molecule in development for anti-circulating calciprotein particle (CPP2) therapy at present and had no influence on the content of this paper. E.R. Smith is a stockholder and former scientific advisor of Calciscon AG and has also received honoraria from CSL Vifor. Funding from Astellas received by R.A. Pol had no influence on the content of the paper. Astellas was not involved in the design of the study, collection of data, analysis and interpretation of data, management, manuscript preparation or the decision to submit the paper for publication. All other authors report no conflict of interest.
: The study was conducted in compliance with the principle of the Declaration of Helsinki. All patients gave written informed consent. The protocol was reviewed and approved by the Institutional Review Board of the UMCG (number 2014–077).
